Larazotide 1mg (30 Capsules)
€295.00
Larazotide acetate is an investigational oral peptide designed to regulate intestinal epithelial tight junctions. Research has primarily focused on its potential to reduce gluten-related intestinal and gastrointestinal effects in people with celiac disease.
In Stock
Description
Fields of Study
- Intestinal epithelial barrier function
- Tight-junction regulation and assembly
- Paracellular intestinal permeability
- Zonulin-associated signaling pathways
- Gliadin-induced intestinal barrier disruption
- Celiac disease
- Tight-junction proteins including ZO-1, occludin and claudins
- Actin cytoskeleton and epithelial junction organization
Potential uses & benefits:
Supports intestinal barrier function: Larazotide has been studied for its ability to help regulate tight-junction activity and limit excessive paracellular passage across the intestinal epithelium.
May reduce gluten-related GI symptoms: Clinical trials in people with celiac disease found that certain doses, including 1 mg, reduced gastrointestinal symptoms during controlled gluten exposure.
May reduce gluten-associated immune activation: In one randomized trial, the 1 mg group had a lower increase in anti-tissue-transglutaminase IgA compared with placebo during gluten challenge.
Locally acting: Larazotide is designed to act within the intestinal tract rather than producing substantial systemic exposure.
Related Research
Gopalakrishnan S, Durai M, Kitchens K, et al.
Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides. 2012;35(1):86–94.
doi:10.1016/j.peptides.2012.02.015. PMID: 22401908. (PubMed)
Gopalakrishnan S, Tripathi A, Tamiz AP, Alkan SS, Pandey NB.
Larazotide acetate promotes tight junction assembly in epithelial cells. Peptides. 2012;35(1):95–101.
doi:10.1016/j.peptides.2012.02.016. PMID: 22401910. (PubMed)
Kelly CP, Green PHR, Murray JA, et al.
Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther. 2013. PMID: 23163616. (PubMed)
Leffler DA, Kelly CP, Green PHR, et al.
Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015. PMID: 25683116. (PubMed)
Khaleghi S, Ju JM, Lamba A, Murray JA.
The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate. Ther Adv Gastroenterol. 2016;9(1):37–49.
doi:10.1177/1756283X15616576. PMID: 26770266. (PubMed)
